Danuglipron is a small-molecule

GLP-1 agonist Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of ...

, formerly under development by

Pfizer Pfizer Inc. ( ) is an American Multinational corporation, multinational Pharmaceutical industry, pharmaceutical and biotechnology corporation headquartered at The Spiral (New York City), The Spiral in Manhattan, New York City. Founded in 184 ...

that, in an oral formulation, was under investigation as a therapy for

diabetes mellitus Diabetes mellitus, commonly known as diabetes, is a group of common endocrine diseases characterized by sustained hyperglycemia, high blood sugar levels. Diabetes is due to either the pancreas not producing enough of the hormone insulin, or th ...

. Initial results from a

randomized controlled trial A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical ...

indicated that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting. However, in April 2025, Pfizer announced it would abandon further development of Danuglipron due to unpredictable liver toxicity.

References

GLP-1 receptor agonists Experimental diabetes drugs Nitriles Fluoroarenes Disubstituted pyridines Ethers Piperidines Oxetanes Benzimidazoles Carboxylic acids Abandoned drugs Hepatotoxins {{Gastrointestinal-drug-stub

See also

References